A government panel in India has recommended that prices for expensive drugs to treat critical diseases like HIV, cancer and hepatitis be based on the nation's per capita income, which could substantially reduce their costs and make them more affordable for patients. Some in the industry warn, however, that the regulations could backfire and instead prevent companies from offering new drugs in India.

Related Summaries